Pneumococcal Vaccines Market| Coherent Market Insights - PowerPoint PPT Presentation

View by Category
About This Presentation

Pneumococcal Vaccines Market| Coherent Market Insights


Read here the latest updates on the Pneumococcal Vaccines Market published by the CMI team. – PowerPoint PPT presentation

Number of Views:1
Date added: 15 September 2020
Slides: 13
Provided by: adwaitcoherent


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Pneumococcal Vaccines Market| Coherent Market Insights

Coherent Marketing Insights
  • Market Research Business Consulting Services
  • https//
  • Covid-19 Impact Tracker

  • Pneumococcal Vaccines Market, by Vaccine Type
    (PCV10, PCV13, and PPSV23), by Distribution
    Channel (Hospital Pharmacies, Retail Pharmacies,
    and Online Pharmacies) - Size, Share, Outlook,
    and Opportunity Analysis, 2018 2026
  • The global pneumococcal vaccines market size is
    estimated to be valued at US 7,376.6 million in
    2018, and is expected to witness a CAGR of 7.5
    over the forecast period (2018 2026).

  • Pneumococcal vaccine is used to prevent infection
    caused by streptococcus pneumoniae bacteria.
    There are two types of pneumococcal vaccines
    pneumococcal conjugate vaccine and pneumococcal
    polysaccharide vaccine.
  • The Centers for Disease Control and Prevention
    (CDC) recommends pneumococcal conjugate vaccine
    for all children younger than two years of age,
    all adults 65 years or older, and for people 2-64
    years old with certain medical conditions. The
    CDC recommends pneumococcal polysaccharide
    vaccine for all adults 65 years or older, people
    2-64 years old with certain medical conditions,
    and adults 19-64 years old who smoke cigarettes.

  • Figure 1. Global Pneumococcal Vaccines Market
    Value (US Mn) and Absolute Opportunity
    Analysis and Forecast

  • Increasing partnership of manufacturers with
    various governments is expected to drive growth
    of the pneumococcal vaccines market
  • High mortality due to pneumonia among the global
    population is expected to increase adoption of
    pneumococcal vaccines over the forecast period.
    For instance, according to the World Health
    Organization (WHO) November 2016, pneumonia
    accounted for 16 of all deaths of children under
    5 years old in 2015, with 920,136 deaths,
  • Furthermore, increasing partnership among Global
    Alliance for Vaccines and Immunization (GAVI) and
    key vendors to deliver pneumococcal vaccines in
    emerging countries is expected to be a
    significant growth factor for the market. For
    instance, in March 2016, GSK (Glaxo Smith Kline)
    announced the introduction of pneumococcal
    vaccine at the lowest price - US 3.05 from 2017,
    a reduction of 10 from the 2016 price (US
    3.40). Such tiered pricing approach enables
    emerging economies to meet demand for vaccines
    for large proportions of the target population.
    This price is set to be available through the
    pilot Advance Market Commitment (AMC) to all GAVI
    countries. Moreover, the vaccine will be sold at
    the same price for 10 years after transition.

Pneumococcal Vaccines Market- Regional Analysis
  • Regional segmentation of the global pneumococcal
    vaccines market by Coherent Market Insights
    comprises North America, Latin America, Europe,
    Asia Pacific, Middle East, and Africa.
  • North America is expected to hold dominant
    position in the pneumococcal vaccines market.
    This is majorly due to presence of key players in
    the region, which are focused on gaining
    regulatory approvals for novel pneumococcal
    vaccines. Moreover, increasing mortality rate
    associated with pneumonia, growing awareness
    regarding pneumonia infection, and its underlying
    symptoms among the U.S. population are expected
    to contribute to significant market growth in the
    region during the forecast period. For instance,
    according to the American Lung Association 2015,
    around 56,832 deaths were registered due to
    pneumonia and influenza in 2013, which combined
    were the eighth leading cause of death in the
  • Growing healthcare infrastructure in emerging
    economies such as India and China and increasing
    initiatives by government bodies to include
    pneumococcal vaccine in their respective
    healthcare immunization programs contribute to
    wider adoption of pneumococcal vaccines in Asia
    Pacific. For instance, in November 2016, China
    Food and Drug Administration (CFDA) approved
    Pfizer, Inc.s pneumococcal vaccine Prevenar 13,
    which is indicated to help prevent pneumococcal
    disease in infants aged between 6 weeks to 15

Figure 2 Global Pneumococcal Vaccines Market
Value (US Mn), By Region

Pneumococcal Vaccines Market- Competitive
  • Various manufacturers are focused on new projects
    that target diseases with no existing vaccine for
    various age groups. For instance, in April 2018,
    Merck, which is also known as MSD outside of the
    U.S. and Canada, started two Phase 3 studies for
    PCV-15 (V114), an investigational polyvalent
    conjugate vaccine against pneumococcal disease.
  • Key players operating in the pneumococcal
    vaccines market include, Pfizer, Inc., Merck
    Co. Inc., and GlaxoSmithKline plc.
  • Moreover, in 2017, the Government of India, in
    collaboration with GAVI, launched Pneumococcal
    Conjugate Vaccine (PCV) vaccines in three states
    of the country at low cost. Furthermore, under
    this partnership, 60 of all GAVI-procured
    vaccines will be manufactured in India.
  • These activities coupled with increasing approval
    of vaccines are expected to support growth of
    Asia Pacific pneumococcal vaccines market over
    the forecast period.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Referance https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions. We are headquartered
    in India, having office at global financial
    capital in the U.S. Our client base includes
    players from across all business verticals in
    over 150 countries worldwide.
  • What We ProvideCustomized Market Research
    AnalysisIndustry Analysis ServicesBusiness
    Consulting ServicesLong Term Engagement
    ModelCountry Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt. LTD.Coherent
    Market Insights 1001 4th Ave, 3200 Seattle, WA
    98154, U.S.Phone 1-206-701-6702
  • Email

Thank You
  • Kindly Follow CMI Social Media Profiles for the
    latest Company Updates.
  • Facebook
  • Linkedin
  • Twitter
  • https//